دورية أكاديمية
Combination therapy with oncolytic viruses and immune checkpoint inhibitors in head and neck squamous cell carcinomas: an approach of complementary advantages
| العنوان: | Combination therapy with oncolytic viruses and immune checkpoint inhibitors in head and neck squamous cell carcinomas: an approach of complementary advantages |
|---|---|
| المؤلفون: | Hui Dong, Mengli Li, Chen Yang, Wei Wei, Xianglei He, Gang Cheng, Shibing Wang |
| المصدر: | Cancer Cell International, Vol 23, Iss 1, Pp 1-17 (2023) |
| بيانات النشر: | BMC, 2023. |
| سنة النشر: | 2023 |
| المجموعة: | LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens LCC:Cytology |
| مصطلحات موضوعية: | Oncolytic viruses, Immune checkpoint inhibitor, Head and neck squamous cell carcinomas, Combination therapy, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282, Cytology, QH573-671 |
| الوصف: | Abstract Squamous cell carcinomas are the most common head and neck malignancies. Significant progress has been made in standard therapeutic methods combining surgery, radiation, and chemotherapy. Nevertheless, the 5-year survival rate remains at 40–50%. Immune checkpoint inhibitors (ICIs) are a new strategy for treating head and neck squamous cell carcinomas (HNSCCs). Still, the overall response and effective rates are poor, as HNSCCs are ‘cold’ tumors with an immunosuppressive tumor microenvironment (TME), limiting ICI’s beneficial effects. In this case, transforming the tumor suppression microenvironment before using ICIs could be helpful. Oncolytic viruses (OVs) can transform cold tumors into hot tumors, improving the situation. Talimogene laherparepvec (T-VEC), oncolytic immunotherapy authorized for advanced melanoma, also showed good safety and antitumor activity in treating head and neck cancer and pancreatic cancer. In combination with pembrolizumab, T-Vec may have more anticancer efficacy than either drug alone. Therefore, understanding the mechanisms underpinning OVs and their potential synergism with ICIs could benefit patients with HNSCC. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 1475-2867 |
| العلاقة: | https://doaj.org/toc/1475-2867Test |
| DOI: | 10.1186/s12935-022-02846-x |
| الوصول الحر: | https://doaj.org/article/b423e4a4f4b947d49d814ba8ed93b56eTest |
| رقم الانضمام: | edsdoj.b423e4a4f4b947d49d814ba8ed93b56e |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | تدمد: | 14752867 |
|---|---|
| DOI: | 10.1186/s12935-022-02846-x |